Rawpixel The FDA has cleared Dexcom’s Stelo Glucose Biosensor System for over-the-counter use by people aged 18 years and older. The system is the first continuous glucose monitor to be made available without a prescription. The device is intended for use by diabetics who treat their condition with oral medications rather than insulin and non-diabetics interested in monitoring their blood glucose levels.
The FDA noted the product should not be used by people with problematic low blood sugar levels as it’s not designed to alert users to the potentially dangerous condition. Dexcom said Stelo will available online without a prescription beginning this summer. More on DexCom DexCom: A Wealth Compounder In Healthcare DexCom, Inc.
(DXCM) Q4 2023 Earnings Call Transcript DexCom, Inc. 2023 Q4 - Results - Earnings Call Presentation Tiger Global exits Alibaba, Pagaya; takes new stakes in DexCom, Broadcom DexCom beats top-line and bottom-line estimates; reaffirms FY24 outlook.
